Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing

International Journal of Clinical Practice

Volumn 57, Issue 8, 2003, Pages 656-661

  Ställberg, Björn ^a,d   Olsson, P ^b   Jorgensen L A ^c   Lindarck, N ^c   Ekstrom T ^c  

^a Trosa Primary Health Care Centre   (Sweden)

^b Primary Health Care Centre   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; SALBUTAMOL; SYMBICORT TURBUHALER; TERBUTALINE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG COST; DRUG SAFETY; FEMALE; HEALTH CARE COST; HUMAN; INHALER; INTERMETHOD COMPARISON; KAPLAN MEIER METHOD; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; STATISTICAL ANALYSIS;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-ASTHMATIC AGENTS; ASTHMA; BUDESONIDE; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0242575119     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Global strategy for asthma management and prevention. Global Initiative for Asthma (GINA). No 02-3659. Bethesda, MD: National Institutes for Health, National Heart, Lung and Blood Institute, 2002.
2. Engel T, Dirksen A, Heinig JH et al. Single-dose inhaled budesonide in subjects with chronic asthma. Allergy 1991; 46: 547-553.
3. Dahl R, Johansson SA. Effect on lung function of budesonide by inhalation, terbutaline s.c. and placebo given simultaneously or as single treatments. Eur J Respir Dis Suppl 1982; 122: 132-137.
4. Ellul-Micallef R, Johansson SA. Acute dose-response studies in bronchial asthma with a new corticosteroid, budesonide. Br J Clin Pharmacol 1983; 15: 419-422.
5. Foresi A, Morelli MC, Catena E, on behalf of the Italian Study Group. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. Chest 2000; 117: 440-446.
6. Pauwels RA, Löfdahl CG, Postma DS et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337: 1405-1411.
7. O'Byrne PM, Barnes PJ, Rodriquez Roisin R et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164: 1392-1397.
8. Palmqvist M, Ibsen T, Mellen A, Lotvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 1999; 160; 244-249.
9. Busse WW, Chervinsky P, Condemi J et al. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol 1998; 101: 457-463.
10. Ankerst J, Persson G, Weibull E. Tolerability of a high dose of budesonide/formoterol in a single inhaler in patients with asthma. Pulm Pharmacol Ther 2003; 16: 147-151.
11. Rosenhall L, Elvstrand A, Tilling B et al. One-year safety and efficacy of budesonide/formoterol in a single inhaler (Symbicort® Turbuhaler®) for the treatment of asthma. Respir Med 2003; 97: 702-708.
12. Gibson PG, Coughlan J, Wilson AJ et al. Self-management education and regular practitioner review for adults with asthma (Cochrane Review). In: The Cochrane Library. 1, 2003. Oxford: Update Software.
13. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive airway disease (COPD) and asthma. Am Rev Respir Dis 1987; 136: 225-244.
14. Andersson F, Kartman B. The cost of angina pectoris in Sweden. Pharmacoeconomics 1995; 8: 233-244.
15. Andersson F, Kjellman M, Forsberg G et al. Comparison of the cost-effectiveness of budesonide and sodium cromoglycate in the management of childhood asthma in everyday clinical practice. Ann Allergy Asthma Immunol 2001; 86; 537-544.
16. Rutten-van Molken MP, van Doorslaer EK, van Vliet RC. Statistical analysis of cost outcomes in a randomized controlled clinical trial. Health Econ 1994; 3: 333-345.
17. Pauwels RA, Campbell M, Villasante C et al. Formoterol (Oxis® Turbuhaler® compared with salbutamol as reliever medication in asthma an exploratory analysis of the RELIEF study in patients using formoterol as maintenance therapy. Eur Respir J 2002; 20(suppl 38): 44s.
18. Tal A. Simon G, Vermeulen JH et al. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatr Pulmonol 2002; 34: 342-350.
19. Zetterström O, Buhl R, Mellem H et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J 2001; 18: 262-268.